42. A method according to claim 36, wherein said cells are CD30+ lymphoma cells.

43. A method according to claim 28, wherein said cells are CD30+ Hodgkin's Disease cells.

44. A method according to claim 34, wherein said cells are CD30+ Hodgkin's Disease cells.

45. A method according to claim 36, wherein said cells are CD30+ Hodgkin's Disease cells.

46. A method according to claim 34, wherein said conjugate comprises a therapeutic agent.

47. A method according to claim 31, wherein said soluble CD30-L is a soluble fragment of the human CD30-L of SEQ ID NO:8, wherein said fragment binds CD30.

48. A method for reducing proliferation of LCAL cells in a human afflicted with LCAL, comprising administering an effective amount of a CD30-L oligomer to said human, wherein said oligomer comprises two or three CD30-L polypeptides, wherein each of said CD30-L polypeptides is a soluble fragment of the human CD30-L of SEQ ID NO:8, wherein said oligomer binds CD30.

49. A method according to claim 48, wherein said oligomer comprises three CD30-L polypeptides.

REMARKS

This amendment is submitted in order to place the subject application in better condition for examination. The amendment also serves to add claims directed to particular embodiments of the invention. Each amended and new claim is fully supported by the application as filed.

The title as amended corresponds to the designation employed in the specification, for the subject cytokine. The remaining amendments to page one insert and update information on related applications.

Claims 27, 28, and 31 are amended due to cancellation of the claims on which original claims 27, 28, and 31 were dependent. New claims 32-49 are supported on page 16, line 20, to page 17, line 15; page 4, lines 15-18; page 7, lines 10-20 and 31-33; page 35, line 34, through page 36, line 1; page 2, lines 35-36; page 3, lines 28-32; and page 14, line 16, to

page 16, line 5 of the present specification as originally filed. Further support is found in the language of claims 29 to 31 as originally filed.

Claims 27-49 are now pending in the subject application.

Respectfully submitted,



Kathryn A. Anderson
Registration No. 32,172

Immunex Corporation
51 University Street
Seattle, Washington 98101
(206) 587-0430